Biohaven .(US:BHVN) Prnewswire·2025-07-31 12:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements about the company's product candidates and their regulatory prospects [1][2]. Summary by Sections Allegations - The complaint alleges that during the class period from March 24, 2023, to May 14, 2025, Biohaven's defendants made materially false and misleading statements regarding: - The regulatory prospects of the product candidate, troriluzole, for treating SCA were overstated [1]. - The efficacy and clinical prospects of BHV-7000 for bipolar disorder were also overstated [1]. - The revelation of these issues is likely to significantly negatively impact Biohaven's business and financial condition [1]. - Consequently, the public statements made by the defendants were materially false and misleading throughout the relevant period [1]. Next Steps for Shareholders - Shareholders who purchased shares of BHVN during the specified timeframe are encouraged to register for the class action by September 12, 2025 [2]. - Registration allows shareholders to be enrolled in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights who have suffered from deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [3].